Categories Earnings, Health Care

Medtronic (MDT) beats Q3 earnings estimates; revenues miss mark

Medtronic plc (NYSE: MDT) topped earnings expectations for the third quarter of 2020 while revenue fell short of estimates. The stock was down 2.8% in premarket hours on Tuesday.

Total revenue of $7.71 billion rose 2.3% from the same period a year ago but came below forecasts of $7.81 billion. On an organic basis, revenues grew 2.6%.

Medtronic (MDT) reports Q3 2020 earnings results

GAAP net income was $1.91 billion, or $1.42 per share. Adjusted net income grew over 11% to $1.94 billion, or $1.44 per share, beating projections of $1.38.  

For fiscal year 2020, adjusted EPS is expected to be $5.63-5.65. For the fourth quarter of 2020, adjusted EPS is expected to be $1.62-1.64.

In the third quarter, revenue in the US inched up 0.5% on a reported basis. Revenues in the non-US developed market rose 0.4% while emerging markets revenue climbed 12%.

Also read: Acasti Pharma Q3 2020 Earnings Snapshot

Revenues in the Cardiac and Vascular Group increased 1.2% during the quarter but the growth was lower than expected as customers refrained from making purchases ahead of new product launches in the Coronary & Structural Heart division. The company also saw a slower-than-expected recovery in left ventricular assist devices.  

Revenues in the Minimally Invasive Therapies Group grew 2.4%, driven by increases in the Surgical Innovations, and Respiratory, Gastrointestinal & Renal divisions. Revenue results in the segment were impacted by an upgrade to its enterprise resource planning system in the US and Canada.  

Revenues in the Restorative Therapies Group rose 4.2%, aided by growth in the Brain Therapies, Spine, and Specialty Therapies divisions. The results were slightly offset by a 3.5% decrease in revenue from Pain Therapies. Revenues in the Diabetes Group remained flat.   

Also Read:  Universal Display stock surges on Q4 earnings beat and increased dividend

During the quarter, Medtronic acquired software company Klue, whose behavior-tracking technology is expected to help in diabetes management by automating insulin delivery through the monitoring of patients’ eating habits.

Last month, the company acquired Stimgenics, the pioneer of a novel spinal cord stimulation waveform known as Differential Target Multiplexed Spinal Cord Stimulation, which is considered a unique option to treat patients with chronic pain. Both deals are expected to be neutral to FY2020 EPS.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

A look at factors that make Snap-on (SNA) a compelling investment option

Snap-on Incorporated (NYSE: SNA), the century-old company that makes high-end tools for the automotive industry, is unlikely to have a smooth ride in the current quarter, given the deepening turmoil

BlackBerry (BB) Q4 2020 earnings call highlights; blames COVID-19 for not providing fiscal 2021 outlook

Immediately after BlackBerry's (NYSE: BB) fourth-quarter 2020 results came out last evening, its stock traded in the green for quite some time in the after-hours. However, when the company announced

Why HP (HPQ) is better off without Xerox (XRX)

Xerox Corp. (NYSE: XRX) has dropped its takeover bid for HP Inc. (NYSE: HPQ) citing difficulties created by the coronavirus outbreak. This could be a relief for HP since the

2 thoughts on “Medtronic (MDT) beats Q3 earnings estimates; revenues miss mark

Comments are closed.

Top